Direct answer: Tirzepatide activates GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors. In the direct SURMOUNT-5 obesity trial, tirzepatide produced greater mean weight loss at 72 weeks. That group comparison does not guarantee an individual result or settle safety, indication, and access questions.
Two molecules, several products
Semaglutide and tirzepatide are prescription active ingredients, not single universal treatment plans. Semaglutide appears in FDA-approved products with different indications and presentations. Tirzepatide also appears in products whose approved use depends on the brand. When the question is weight management, the most direct branded comparison is Wegovy versus Zepbound.
Using Ozempic, Wegovy, Mounjaro, Zepbound, and compounded versions as interchangeable names creates inaccurate comparisons. Dose range, population, device, label, and quality oversight can differ. Always identify the exact product before using a study to support a claim.
Because the same two ingredients travel under so many product names, comparison explainers are everywhere online. Ro, Hims and Hers, and HealthRX each host a semaglutide vs tirzepatide overview, so reading several against the actual FDA labels is safer than trusting any one provider’s summary.
How the receptor mechanisms differ
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. These pathways influence glucose-dependent insulin secretion, appetite, food intake, and gastric emptying. Tirzepatide’s dual activity is a meaningful pharmacologic difference, but it should not be turned into a simplistic promise that two receptors always produce a particular outcome.
A mechanism is biological context. Clinical trials measure what happened to groups of people under defined conditions. Both are useful, but measured outcomes should lead any effectiveness comparison.
The direct SURMOUNT-5 result
Researchers in SURMOUNT-5 enrolled 751 participants who had obesity but not diabetes. The randomized groups used their maximum tolerated therapy, either 10 or 15 mg of tirzepatide or 1.7 or 2.4 mg of semaglutide. After 72 weeks, the average reduction from initial weight was 20.2 percent in the tirzepatide arm and 13.7 percent in the semaglutide arm. Waist measurement also decreased more in the tirzepatide group.
This trial resolves a weakness in older articles that compared SURMOUNT-1 with STEP 1 as though the studies were a single contest. Separate trials can differ in population, procedures, adherence, and statistical methods. A randomized head-to-head design makes the relative result more interpretable.
Limits still matter. Diabetes was an exclusion, only defined dose ranges were studied, observation ended at week 72, and Eli Lilly funded the work. These are group estimates rather than a promised trajectory, and they need to be weighed against personal factors the trial did not measure.
What expected results actually means
A trial mean is the average of varied experiences. Some participants lose more, some less, and some stop because of adverse events or other reasons. A percentage also needs a time point, product, dose strategy, population, and analysis method. Removing those qualifiers makes a precise number misleading.
Expected results should include more than weight. Depending on the diagnosis and product, a clinician may monitor waist circumference, blood pressure, glycemic measures, sleep-apnea symptoms, cardiovascular risk, liver-related measures, nutrition, function, and quality of life. The meaningful target should be agreed before treatment and reassessed rather than inferred from a viral transformation.
Study completion is another useful qualifier. Reported estimates may use statistical approaches for missing data or treatment discontinuation, so a headline number is not simply the experience of every person who began therapy. Read the methods and estimand before comparing percentages from different publications.
Approved uses are not identical
The current Wegovy label covers two presentations, an injection and an oral tablet, so semaglutide for weight management is no longer an injection-only decision. The injection is indicated for long-term weight management in adults and in pediatric patients aged 12 and older with obesity, for cardiovascular event-risk reduction in qualifying adults who already have cardiovascular disease, and under accelerated approval for noncirrhotic MASH with F2 or F3 fibrosis in adults. The tablet carries the weight management and cardiovascular indications but not the MASH one. Zepbound’s current label addresses long-term weight management and moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro, the other tirzepatide product, is indicated for type 2 diabetes in adults and in pediatric patients aged 10 and older.
Those differences can be clinically important, but they do not mean a listed condition automatically selects the medicine. The prescriber must confirm eligibility, contraindications, competing priorities, and whether the evidence applies to the patient.
Shared safety themes and distinct label details
Each product has the FDA’s strongest warning format for the thyroid C-cell tumor concern seen in animal studies. A history of medullary thyroid carcinoma in the patient or family, or a diagnosis of MEN 2, is a contraindication. Label precautions also cover pancreatic inflammation, gallbladder events, volume-depletion kidney injury, serious gastrointestinal reactions, allergy, low glucose in some diabetes regimens, pregnancy, and slowed stomach emptying.
The details are not perfectly identical. Other medicines, oral contraceptive use, planned procedures, diabetic retinopathy, and previous adverse reactions deserve product-specific review. Digestive-system events dominated the adverse-event reports in SURMOUNT-5, usually during titration and at mild or moderate severity. Higher average efficacy does not imply easier tolerability, and the two questions should be answered separately.
Real-world results depend on continuity
Trials provide medicine, structured follow-up, and defined procedures. Outside a trial, insurance changes, shortages, self-pay offers, missed refills, and inconsistent follow-up can interrupt treatment. A realistic comparison includes whether the product can be obtained and monitored over time.
Current cost should be checked through the insurer, pharmacy, official manufacturer program, or Medicare pathway that applies on the decision date. Do not use an old list price as an estimate of what a specific person will pay. Cash-pay telehealth is a separate lane, with services such as Ro, LifeMD, and formblends.com quoting a flat monthly figure outside the pharmacy benefit; several of them dispense compounded semaglutide or tirzepatide, which is not an FDA-approved product and was not what SURMOUNT-5 studied.
Follow-up also affects how results are interpreted. Weight change without information about adverse effects, nutrition, function, adherence, and treatment interruption can create a false picture of success. A useful plan names the outcome measures, reassessment point, and circumstances that would lead to continuing, changing, or stopping treatment.
Why compounded products need a separate evidence statement
FDA-approved products undergo premarket evaluation for safety, effectiveness, and quality. Compounded drugs do not. A compound may be appropriate for an identified patient in legally permitted circumstances, but it should not be marketed as automatically equivalent to the product used in SURMOUNT-5.
Ask which ingredient form is used, which licensed pharmacy dispenses it, why compounding is clinically necessary, and what labeling, storage, and adverse-event process applies. Do not transfer branded trial percentages to an unspecified compounded vial.
Bottom line
The strongest current comparative evidence supports greater average 72-week weight loss with tirzepatide in adults with obesity without diabetes. Semaglutide and tirzepatide remain distinct treatments with product-specific indications, precautions, presentations, and access pathways. The best clinical choice requires more than a ranking.
The useful next step is to turn the trial data into questions: which product, which indication, which dose range, and whether the treatment can be sustained long enough for the 72-week figures to mean anything.
Frequently asked questions
Does tirzepatide work twice as well because it targets two receptors?
No. Receptor count is not a linear effectiveness formula. Use direct clinical outcomes with their population and time limits.
Did SURMOUNT-5 compare Zepbound with Wegovy doses?
It compared tirzepatide 10 or 15 mg with semaglutide 1.7 or 2.4 mg using maximum tolerated doses in adults with obesity without diabetes.
Are results the same in type 2 diabetes?
Do not assume so. People with diabetes were excluded, and diabetes-specific evidence should be considered.
Can I predict my result from the average?
No. The mean describes the study group. Individual response, adherence, tolerability, and continuity vary.
